CEO Martin Nicklasson leaves Swedish Orphan Biovitrum
(Thomson Reuters ONE) -
Stockholm, Sweden November 25, 2010 - Swedish Orphan Biovitrum (STO:SOBI) today
announced that CEO Martin Nicklasson will leave the company. The search for a
new CEO will be initiated immediately. Kennet Rooth, currently head of
marketing and sales, has agreed to assume the position as interim CEO for SOBI.
Based upon the growth aspirations, the emerging late stage clinical development
pipeline and the continuous increasing commercial portfolio, Swedish Ophan
Biovitrum is entering into a new phase in its development. Therefore, the board
of directors initiated a dialogue with CEO Martin Nicklasson regarding the
profile needed to match the next phase the company is entering into. The Board
of Directors and Martin Nicklasson have jointly come to the conclusion that a
new leadership is desired for the company going forward. Kennet Rooth, currently
Head of Sales and Marketing, has agreed to stay with the company and assume the
position as interim CEO for SOBI until a new CEO has been recruited. Martin
Nicklasson will leave SOBI on January 1, 2011.
"On the behalf of the whole board we want to express our gratitude to the
excellent job that Martin Nicklasson has done over the last 3 years. Martin has
been material in transforming Biovitrum from a research company focusing on
small molecular drugs, to become a niche specialty pharma leader in the field of
rare diseases with an attractive pipeline of biological drugs. With the recent
acquisition and integration of Swedish Orphan International, Martin hands over a
well-reputed leading international company and a platform to build further on",
says SOBI's Chairman Bo Jesper Hansen.
"After the successful transformation of Biovitrum, followed by the creation of
SOBI, now is a good time for a new leader to take the company forward into the
future. I will now have the opportunity to evaluate different non-executive
opportunities, says Martin Nicklasson.
For more information please contact
Bo Jesper Hansen, Chairman of the Board
Phone: +46 767 82 02 83
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a Swedish based orphan drug niche specialty
pharmaceutical company with an international market presence. The company is
focused on providing and developing specialist pharmaceuticals for rare disease
patients and for patients with high unmet medical needs. The portfolio consists
of about 60 marketed products and an emerging late stage clinical development
pipe-line. Our focus areas are: hemophilia, inflammation/autoimmune diseases,
fat malabsorption, cancer and inherited metabolic disorders. Swedish Orphan
Biovitrum had pro-forma revenues 2009e of about 2 BSEK and approximately 500
employees. The head office is located in Sweden and the share (STO: SOBI) is
listed on NASDAQ OMX Stockholm. For more information please visitwww.sobi.com.
Swedish Orphan Biovitrum may be required to disclose the information provided
herein pursuant to the Swedish Securities Markets Act. The information was
provided for public release on November 25, 2010 at 8:30 a.m. CET.
[HUG#1465404]
Press release November 25 in PDF format:
http://hugin.info/134557/R/1465404/403605.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 25.11.2010 - 08:31 Uhr
Sprache: Deutsch
News-ID 49099
Anzahl Zeichen: 4186
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 223 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CEO Martin Nicklasson leaves Swedish Orphan Biovitrum"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
